16 results on '"Stechemesser, Lars"'
Search Results
2. Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism
- Author
-
Stechemesser, Lars, Eder, Sebastian K., Wagner, Andrej, Patsch, Wolfgang, Feldman, Alexandra, Strasser, Michael, Auer, Simon, Niederseer, David, Huber-Schönauer, Ursula, Paulweber, Bernhard, Zandanell, Stephan, Ruhaltinger, Sandra, Weghuber, Daniel, Haschke-Becher, Elisabeth, Grabmer, Christoph, Rohde, Eva, Datz, Christian, Felder, Thomas K., and Aigner, Elmar
- Published
- 2017
- Full Text
- View/download PDF
3. Wiener klinische Wochenschrift volume / Diabetes mellitus und Straßenverkehr – ein Positionspapier der Österreichischen Diabetesgesellschaft (Update 2023) : Diabetes mellitus and road traffic—a position paper of the Austrian Diabetes Association (update 2023)
- Author
-
Clodi, Martin, Abrahamian, Heidemarie, Salamon, Birgit, Lahnsteiner, Angelika, Schelkshorn, Christian, Bräuer, Alexander, Stechemesser, Lars, and Köhler, Gerd
- Subjects
Folgeschäden ,Gesetzliche Grundlagen ,Diabetes mellitus ,Driving safety ,Fahrsicherheit ,Hypoglykämiewahrnehmungsstörung ,Driving license ,Hypoglycemia unawareness ,Führerschein ,Hypoglykämien ,Legal regulations ,Hypoglycemia ,Late complications - Abstract
Bei der Beurteilung der gesundheitlichen Eignung zum Lenken eines Kraftfahrzeuges ist die öffentliche Sicherheit (Unfallprävention) das vorrangige Ziel. Der generelle Zugang zu Mobilität sollte jedoch nicht eingeschränkt werden, wenn kein besonderes Risiko für die öffentliche Sicherheit besteht. Für Menschen mit Diabetes mellitus sind im Führerscheingesetz (FSG) und in der Führerscheingesetz-Gesundheitsversorgung (FSG-GV) wichtige Aspekte zur Fahrsicherheit in Zusammenhang mit akuten und chronischen Komplikationen der Erkrankung geregelt. Zu den kritischen Komplikationen, die für die Verkehrssicherheit relevant sind, gehören schwere Hypoglykämie, ausgeprägte Hyperglykämie und Hypoglykämiewahrnehmungsstörung, sowie schwere Retinopathie und Neuropathie, weiters fortgeschrittene Nierenerkrankung und bestimmte kardiovaskuläre Manifestationen. Bei Verdacht auf Präsenz einer dieser Akutkomplikationen oder Folgeschäden ist eine genaue Evaluierung erforderlich. Darüber hinaus ist die individuelle antihyperglykämische Medikation auf vorhandenes Potenzial für Hypoglykämien zu überprüfen. Sulfonylharnstoffe, Glinide und Insulin gehören in diese Gruppe und sind daher automatisch mit der Auflage einer 5‑jährigen Befristung des Führerscheines assoziiert. Metformin, DPP-4-Hemmer (Dipeptidyl-Peptidase-4-Hemmer, Gliptine), SGLT2-Hemmer (Sodium-dependent-glucose-transporter‑2 inhibitors, Gliflozine), Glitazone und die zu injizierenden GLP-1 Analoga (GLP‑1 Rezeptor Agonisten) weisen kein Hypoglykämiepotential auf und sind daher nicht mit einer Befristung verbunden. Die FSG-GV gibt Spielraum für Interpretation, sodass im Folgenden spezifische Themen zur Fahrsicherheit für Menschen mit Diabetes mellitus aus fachärztlicher und verkehrsrelevanter Sicht aufgearbeitet wurden. Dieses Positionspapier dient zur Unterstützung von Personen, die mit dieser herausfordernden Materie befasst sind. Public safety (prevention of accidents) is the primary objective in assessing fitness to drive a motor vehicle. However, general access to mobility should not be restricted if there is no particular risk to public safety. For people with diabetes mellitus, the Führerscheingesetz (Driving Licence Legislation) and the Führerscheingesetz—Gesundheitsverordnung (Driving Licence Legislation Health enactment) regulate important aspects of driving safety in connection with acute and chronic complications of the disease. Critical complications that may be relevant to road safety include severe hypoglycemia, pronounced hyperglycemia and hypoglycemia perception disorder as well as severe retinopathy and neuropathy, endstage renal disease and certain cardiovascular manifestations. If there is a suspicion of the presence of one of these complications, a detailed evaluation is required. In addition, the individual antihyperglycemic medication should be checked for existing potential for hypoglycemia. Sulfonylureas, glinides and insulin belong to this group and are therefore associated with the requirement of a 5-year limitation of the driver’s license. Other antihyperglycemic drugs without potential for hypoglycemia such as Metformin, SGLT‑2 inhibitors (Sodium-dependent-glucose-transporter‑2 inhibitors, gliflozins), DPP-4-inhibitors (Dipeptidyl-Peptidase inhibitors, gliptins), and GLP‑1 analogues (GLP‑1 rezeptor agonists) are not associated with such a time limitation. The relevant laws which regulate driving safety give room for interpretation, so that specific topics on driving safety for people with diabetes mellitus are elaborated from a medical and traffic-relevant point of view. This position paper is intended to support people involved in this challenging matter. Version of record
- Published
- 2023
- Full Text
- View/download PDF
4. Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria
- Author
-
The FinnDiane Study Group, Jansson Sigfrids, Fanny, Stechemesser, Lars, Dahlström, Emma H., Forsblom, Carol M., Harjutsalo, Valma, Weitgasser, Raimund, Taskinen, Marja Riitta, Groop, Per Henrik, HUS Abdominal Center, Nefrologian yksikkö, CAMM - Research Program for Clinical and Molecular Metabolism, University of Helsinki, Clinicum, Research Programs Unit, Marja-Riitta Taskinen Research Group, HUS Heart and Lung Center, Department of Medicine, and Per Henrik Groop / Principal Investigator
- Subjects
medicine.medical_specialty ,NEPHROPATHY ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Diabetic nephropathy ,03 medical and health sciences ,0302 clinical medicine ,INFLAMMATION ,cardiovascular disease ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,Albuminuria ,Humans ,Diabetic Nephropathies ,Myocardial infarction ,Finland ,RISK ,Type 1 diabetes ,Apolipoprotein C-III ,business.industry ,diabetic nephropathy ,CHOLESTEROL ,Hazard ratio ,dyslipidemia ,ASSOCIATION ,medicine.disease ,mortality ,INSULIN ,3. Good health ,type 1 ,Diabetes Mellitus, Type 1 ,Cardiovascular Diseases ,3121 General medicine, internal medicine and other clinical medicine ,Cohort ,diabetes mellitus ,ENDOTHELIAL DYSFUNCTION ,Cardiology ,CORONARY-ARTERY-DISEASE ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,business ,Mace ,CIII - Abstract
Publisher Copyright: © 2021 The Association for the Publication of the Journal of Internal Medicine Objectives: We studied apolipoprotein C-III (apoC-III) in relation to diabetic kidney disease (DKD), cardiovascular outcomes, and mortality in type 1 diabetes. Methods: The cohort comprised 3966 participants from the prospective observational Finnish Diabetic Nephropathy Study. Progression of DKD was determined from medical records. A major adverse cardiac event (MACE) was defined as acute myocardial infarction, coronary revascularization, stroke, or cardiovascular mortality through 2017. Cardiovascular and mortality data were retrieved from national registries. Results: ApoC-III predicted DKD progression independent of sex, diabetes duration, blood pressure, HbA1c, smoking, LDL-cholesterol, lipid-lowering medication, DKD category, and remnant cholesterol (hazard ratio [HR] 1.43 [95% confidence interval 1.05–1.94], p = 0.02). ApoC-III also predicted the MACE in a multivariable regression analysis; however, it was not independent of remnant cholesterol (HR 1.05 [0.81–1.36, p = 0.71] with remnant cholesterol; 1.30 [1.03–1.64, p = 0.03] without). DKD-specific analyses revealed that the association was driven by individuals with albuminuria, as no link between apoC-III and the outcome was observed in the normal albumin excretion or kidney failure categories. The same was observed for mortality: Individuals with albuminuria had an adjusted HR of 1.49 (1.03–2.16, p = 0.03) for premature death, while no association was found in the other groups. The highest apoC-III quartile displayed a markedly higher risk of MACE and death than the lower quartiles; however, this nonlinear relationship flattened after adjustment. Conclusions: The impact of apoC-III on MACE risk and mortality is restricted to those with albuminuria among individuals with type 1 diabetes. This study also revealed that apoC-III predicts DKD progression, independent of the initial DKD category.
- Published
- 2021
5. COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age—Propensity Score-Matched Analysis of Austrian National Public Health Institute Data
- Author
-
Aziz, Faisal, primary, Aberer, Felix, additional, Bräuer, Alexander, additional, Ciardi, Christian, additional, Clodi, Martin, additional, Fasching, Peter, additional, Karolyi, Mario, additional, Kautzky-Willer, Alexandra, additional, Klammer, Carmen, additional, Malle, Oliver, additional, Pawelka, Erich, additional, Pieber, Thomas, additional, Peric, Slobodan, additional, Ress, Claudia, additional, Schranz, Michael, additional, Sourij, Caren, additional, Stechemesser, Lars, additional, Stingl, Harald, additional, Stöcher, Hannah, additional, Stulnig, Thomas, additional, Tripolt, Norbert, additional, Wagner, Michael, additional, Wolf, Peter, additional, Zitterl, Andreas, additional, Reisinger, Alexander Christian, additional, Siller-Matula, Jolanta, additional, Hummer, Michael, additional, Moser, Othmar, additional, von-Lewinski, Dirk, additional, Eller, Philipp, additional, Kaser, Susanne, additional, and Sourij, Harald, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Biomarkers Predictive for In-Hospital Mortality in Patients with Diabetes Mellitus and Prediabetes Hospitalized for COVID-19 in Austria: An Analysis of COVID-19 in Diabetes Registry.
- Author
-
Aziz, Faisal, Stöcher, Hannah, Bräuer, Alexander, Ciardi, Christian, Clodi, Martin, Fasching, Peter, Karolyi, Mario, Kautzky-Willer, Alexandra, Klammer, Carmen, Malle, Oliver, Aberer, Felix, Pawelka, Erich, Peric, Slobodan, Ress, Claudia, Sourij, Caren, Stechemesser, Lars, Stingl, Harald, Stulnig, Thomas, Tripolt, Norbert, and Wagner, Michael
- Subjects
HOSPITAL mortality ,DIABETES ,PEOPLE with diabetes ,TYPE 1 diabetes ,TYPE 2 diabetes ,PREDIABETIC state - Abstract
Background: This study assessed the predictive performance of inflammatory, hepatic, coagulation, and cardiac biomarkers in patients with prediabetes and diabetes mellitus hospitalized for COVID-19 in Austria. Methods: This was an analysis of a multicenter cohort study of 747 patients with diabetes mellitus or prediabetes hospitalized for COVID-19 in 11 hospitals in Austria. The primary outcome of this study was in-hospital mortality. The predictor variables included demographic characteristics, clinical parameters, comorbidities, use of medication, disease severity, and laboratory measurements of biomarkers. The association between biomarkers and in-hospital mortality was assessed using simple and multiple logistic regression analyses. The predictive performance of biomarkers was assessed using discrimination and calibration. Results: In our analysis, 70.8% had type 2 diabetes mellitus, 5.8% had type 1 diabetes mellitus, 14.9% had prediabetes, and 8.6% had other types of diabetes mellitus. The mean age was 70.3 ± 13.3 years, and 69.3% of patients were men. A total of 19.0% of patients died in the hospital. In multiple logistic regression analysis, LDH, CRP, IL-6, PCT, AST-ALT ratio, NT-proBNP, and Troponin T were significantly associated with in-hospital mortality. The discrimination of NT-proBNP was 74%, and that of Troponin T was 81%. The calibration of NT-proBNP was adequate (p = 0.302), while it was inadequate for Troponin T (p = 0.010). Conclusion: Troponin T showed excellent predictive performance, while NT-proBNP showed good predictive performance for assessing in-hospital mortality in patients with diabetes mellitus hospitalized with COVID-19. Therefore, these cardiac biomarkers may be used for prognostication of COVID-19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. 1627-P: Real-World Comparison of Acute Complications in Adult Patients with Type 1 Diabetes in U.S. and European Registries
- Author
-
ZHOU, FANG L., primary, HERMANN, JULIA, additional, PETTUS, JEREMY, additional, KERNER, WOLFGANG, additional, MILLER, KELLEE, additional, STECHEMESSER, LARS, additional, EDELMAN, STEVEN, additional, IBALD-MULLI, ANGELA M., additional, and HOLL, REINHARD W., additional
- Published
- 2020
- Full Text
- View/download PDF
8. Apolipoprotein C‐III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria.
- Author
-
Jansson Sigfrids, Fanny, Stechemesser, Lars, Dahlström, Emma H., Forsblom, Carol M., Harjutsalo, Valma, Weitgasser, Raimund, Taskinen, Marja‐Riitta, and Groop, Per‐Henrik
- Subjects
- *
APOLIPOPROTEIN C , *TYPE 1 diabetes , *DIABETIC nephropathies , *MAJOR adverse cardiovascular events , *ALBUMINURIA - Abstract
Objectives: We studied apolipoprotein C‐III (apoC‐III) in relation to diabetic kidney disease (DKD), cardiovascular outcomes, and mortality in type 1 diabetes. Methods: The cohort comprised 3966 participants from the prospective observational Finnish Diabetic Nephropathy Study. Progression of DKD was determined from medical records. A major adverse cardiac event (MACE) was defined as acute myocardial infarction, coronary revascularization, stroke, or cardiovascular mortality through 2017. Cardiovascular and mortality data were retrieved from national registries. Results: ApoC‐III predicted DKD progression independent of sex, diabetes duration, blood pressure, HbA1c, smoking, LDL‐cholesterol, lipid‐lowering medication, DKD category, and remnant cholesterol (hazard ratio [HR] 1.43 [95% confidence interval 1.05–1.94], p = 0.02). ApoC‐III also predicted the MACE in a multivariable regression analysis; however, it was not independent of remnant cholesterol (HR 1.05 [0.81–1.36, p = 0.71] with remnant cholesterol; 1.30 [1.03–1.64, p = 0.03] without). DKD‐specific analyses revealed that the association was driven by individuals with albuminuria, as no link between apoC‐III and the outcome was observed in the normal albumin excretion or kidney failure categories. The same was observed for mortality: Individuals with albuminuria had an adjusted HR of 1.49 (1.03–2.16, p = 0.03) for premature death, while no association was found in the other groups. The highest apoC‐III quartile displayed a markedly higher risk of MACE and death than the lower quartiles; however, this nonlinear relationship flattened after adjustment. Conclusions: The impact of apoC‐III on MACE risk and mortality is restricted to those with albuminuria among individuals with type 1 diabetes. This study also revealed that apoC‐III predicts DKD progression, independent of the initial DKD category. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. [Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)]
- Author
-
Clodi, Martin, Abrahamian, Heidemarie, Brath, Helmut, Brix, Johanna, Drexel, Heinz, Fasching, Peter, Föger, Bernhard, Francesconi, Claudia, Fröhlich-Reiterer, Elke, Harreiter, Jürgen, Hofer, Sabine E, Hoppichler, Friedrich, Huber, Joakim, Kaser, Susanne, Kautzky-Willer, Alexandra, Lechleitner, Monika, Ludvik, Bernhard, Luger, Anton, Mader, Julia K, Paulweber, Bernhard, Pieber, Thomas, Prager, Rudolf, Rami-Merhar, Birgit, Resl, Michael, Riedl, Michaela, Roden, Michael, Saely, Christoph H, Schelkshorn, Christian, Schernthaner, Guntram, Sourij, Harald, Stechemesser, Lars, Stingl, Harald, Toplak, Hermann, Wascher, Thomas C, Weitgasser, Raimund, Winhofer-Stöckl, Yvonne, and Zlamal-Fortunat, Sandra
- Subjects
Blood Glucose ,Diabetes Mellitus, Type 2 ,Hyperglycemia ,Practice Guidelines as Topic ,Humans ,Hypoglycemic Agents ,610 Medicine & health ,Life Style - Abstract
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
- Published
- 2019
- Full Text
- View/download PDF
10. Type III Allergy to Insulin Detemir: Response to Darmon et al.
- Author
-
STECHEMESSER, LARS, HOFMANN, MANUELA, HAWRANEK, THOMAS, and WEITGASSER, RAIMUND
- Published
- 2006
11. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen
- Author
-
Salem, Rany M., Todd, Jennifer N., Sandholm, Niina, Cole, Joanne B., Chen, Wei-Min, Andrews, Darrell, Pezzolesi, Marcus G., McKeigue, Paul M., Hiraki, Linda T., Qiu, Chengxiang, Nair, Viji, Di Liao, Chen, Cao, Jing Jing, Valo, Erkka, Onengut-Gumuscu, Suna, Smiles, Adam M., McGurnaghan, Stuart J., Haukka, Jani K., Harjutsalo, Valma, Brennan, Eoin P., van Zuydam, Natalie, Ahlqvist, Emma, Doyle, Ross, Ahluwalia, Tarunveer S., Lajer, Maria, Hughes, Maria F., Park, Jihwan, Skupien, Jan, Spiliopoulou, Athina, Liu, Andrew, Menon, Rajasree, Boustany-Kari, Carine M., Kang, Hyun M., Nelson, Robert G., Klein, Ronald, Klein, Barbara E., Lee, Kristine E., Gao, Xiaoyu, Mauer, Michael, Maestroni, Silvia, Caramori, Maria Luiza, de Boer, Ian H., Miller, Rachel G., Guo, Jingchuan, Boright, Andrew P., Tregouet, David, Gyorgy, Beata, Snell-Bergeon, Janet K., Maahs, David M., Bull, Shelley B., Canty, Angelo J., Palmer, Colin N. A., Stechemesser, Lars, Paulweber, Bernhard, Weitgasser, Raimund, Sokolovska, Jelizaveta, Rovite, Vita, Pirags, Valdis, Prakapiene, Edita, Radzeviciene, Lina, Verkauskiene, Rasa, Panduru, Nicolae Mircea, Groop, Leif C., McCarthy, Mark, I, Gu, Harvest F., Möllsten, Anna, Falhammar, Henrik, Brismar, Kerstin, Martin, Finian, Rossing, Peter, Costacou, Tina, Zerbini, Gianpaolo, Marre, Michel, Hadjadj, Samy, McKnight, Amy J., Forsblom, Carol, McKay, Gareth, Godson, Catherine, Maxwell, A. Peter, Kretzler, Matthias, Susztak, Katalin, Colhoun, Helen M., Krolewski, Andrzej, Paterson, Andrew D., Groop, Per-Henrik, Rich, Stephen S., Hirschhorn, Joel N., Florez, Jose C., Salem, Rany M., Todd, Jennifer N., Sandholm, Niina, Cole, Joanne B., Chen, Wei-Min, Andrews, Darrell, Pezzolesi, Marcus G., McKeigue, Paul M., Hiraki, Linda T., Qiu, Chengxiang, Nair, Viji, Di Liao, Chen, Cao, Jing Jing, Valo, Erkka, Onengut-Gumuscu, Suna, Smiles, Adam M., McGurnaghan, Stuart J., Haukka, Jani K., Harjutsalo, Valma, Brennan, Eoin P., van Zuydam, Natalie, Ahlqvist, Emma, Doyle, Ross, Ahluwalia, Tarunveer S., Lajer, Maria, Hughes, Maria F., Park, Jihwan, Skupien, Jan, Spiliopoulou, Athina, Liu, Andrew, Menon, Rajasree, Boustany-Kari, Carine M., Kang, Hyun M., Nelson, Robert G., Klein, Ronald, Klein, Barbara E., Lee, Kristine E., Gao, Xiaoyu, Mauer, Michael, Maestroni, Silvia, Caramori, Maria Luiza, de Boer, Ian H., Miller, Rachel G., Guo, Jingchuan, Boright, Andrew P., Tregouet, David, Gyorgy, Beata, Snell-Bergeon, Janet K., Maahs, David M., Bull, Shelley B., Canty, Angelo J., Palmer, Colin N. A., Stechemesser, Lars, Paulweber, Bernhard, Weitgasser, Raimund, Sokolovska, Jelizaveta, Rovite, Vita, Pirags, Valdis, Prakapiene, Edita, Radzeviciene, Lina, Verkauskiene, Rasa, Panduru, Nicolae Mircea, Groop, Leif C., McCarthy, Mark, I, Gu, Harvest F., Möllsten, Anna, Falhammar, Henrik, Brismar, Kerstin, Martin, Finian, Rossing, Peter, Costacou, Tina, Zerbini, Gianpaolo, Marre, Michel, Hadjadj, Samy, McKnight, Amy J., Forsblom, Carol, McKay, Gareth, Godson, Catherine, Maxwell, A. Peter, Kretzler, Matthias, Susztak, Katalin, Colhoun, Helen M., Krolewski, Andrzej, Paterson, Andrew D., Groop, Per-Henrik, Rich, Stephen S., Hirschhorn, Joel N., and Florez, Jose C.
- Abstract
Background: Although diabetic kidney disease demonstrates both familial clustering and single nucleotide polymorphism heritability, the specific genetic factors influencing risk remain largely unknown. Methods: To identify genetic variants predisposing to diabetic kidney disease, we performed genome-wide association study (GWAS) analyses. Through collaboration with the Diabetes Nephropathy Collaborative Research Initiative, we assembled a large collection of type 1 diabetes cohorts with harmonized diabetic kidney disease phenotypes. We used a spectrum of ten diabetic kidney disease definitions based on albuminuria and renal function. Results: Our GWAS meta-analysis included association results for up to 19,406 individuals of European descent with type 1 diabetes. We identified 16 genome-wide significant risk loci. The variant with the strongest association (rs55703767) is a common missense mutation in the collagen type IV alpha 3 chain (COL4A3) gene, which encodes a major structural component of the glomerular basement membrane (GBM). Mutations in COL4A3 are implicated in heritable nephropathies, including the progressive inherited nephropathy Alport syndrome. The rs55703767 minor allele (Asp326Tyr) is protective against several definitions of diabetic kidney disease, including albuminuria and ESKD, and demonstrated a significant association with GBM width; protective allele carriers had thinner GBM before any signs of kidney disease, and its effect was dependent on glycemia. Three other loci are in or near genes with known or suggestive involvement in this condition (BMP7) or renal biology (COLEC11 and DDR1). Conclusions: The 16 diabetic kidney disease–associated loci may provide novel insights into the pathogenesis of this condition and help identify potential biologic targets for prevention and treatment.
- Published
- 2019
- Full Text
- View/download PDF
12. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients
- Author
-
Denkmayr, Lukas, primary, Feldman, Alexandra, additional, Stechemesser, Lars, additional, Eder, Sebastian, additional, Zandanell, Stephan, additional, Schranz, Michael, additional, Strasser, Michael, additional, Huber-Schönauer, Ursula, additional, Buch, Stephan, additional, Hampe, Jochen, additional, Paulweber, Bernhard, additional, Lackner, Carolin, additional, Haufe, Heike, additional, Sotlar, Karl, additional, Datz, Christian, additional, and Aigner, Elmar, additional
- Published
- 2018
- Full Text
- View/download PDF
13. Apolipoprotein C3 and Cardiovascular Disease in Patients with Type 1 Diabetes and Diabetic Nephropathy
- Author
-
STECHEMESSER, LARS, primary, FORSBLOM, CAROL, additional, WEITGASSER, RAIMUND, additional, and GROOP, PER-HENRIK, additional
- Published
- 2018
- Full Text
- View/download PDF
14. Training of Carbohydrate Estimation for People with Diabetes Using Mobile Augmented Reality
- Author
-
Domhardt, Michael, primary, Tiefengrabner, Martin, additional, Dinic, Radomir, additional, Fötschl, Ulrike, additional, Oostingh, Gertie J., additional, Stütz, Thomas, additional, Stechemesser, Lars, additional, Weitgasser, Raimund, additional, and Ginzinger, Simon W., additional
- Published
- 2015
- Full Text
- View/download PDF
15. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen.
- Author
-
Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, Pezzolesi MG, McKeigue PM, Hiraki LT, Qiu C, Nair V, Di Liao C, Cao JJ, Valo E, Onengut-Gumuscu S, Smiles AM, McGurnaghan SJ, Haukka JK, Harjutsalo V, Brennan EP, van Zuydam N, Ahlqvist E, Doyle R, Ahluwalia TS, Lajer M, Hughes MF, Park J, Skupien J, Spiliopoulou A, Liu A, Menon R, Boustany-Kari CM, Kang HM, Nelson RG, Klein R, Klein BE, Lee KE, Gao X, Mauer M, Maestroni S, Caramori ML, de Boer IH, Miller RG, Guo J, Boright AP, Tregouet D, Gyorgy B, Snell-Bergeon JK, Maahs DM, Bull SB, Canty AJ, Palmer CNA, Stechemesser L, Paulweber B, Weitgasser R, Sokolovska J, Rovīte V, Pīrāgs V, Prakapiene E, Radzeviciene L, Verkauskiene R, Panduru NM, Groop LC, McCarthy MI, Gu HF, Möllsten A, Falhammar H, Brismar K, Martin F, Rossing P, Costacou T, Zerbini G, Marre M, Hadjadj S, McKnight AJ, Forsblom C, McKay G, Godson C, Maxwell AP, Kretzler M, Susztak K, Colhoun HM, Krolewski A, Paterson AD, Groop PH, Rich SS, Hirschhorn JN, and Florez JC
- Subjects
- Cohort Studies, Female, Humans, Male, Autoantigens genetics, Collagen Type IV genetics, Diabetes Mellitus, Type 1 genetics, Diabetic Nephropathies genetics, Genome-Wide Association Study, Glomerular Basement Membrane, Mutation
- Abstract
Background: Although diabetic kidney disease demonstrates both familial clustering and single nucleotide polymorphism heritability, the specific genetic factors influencing risk remain largely unknown., Methods: To identify genetic variants predisposing to diabetic kidney disease, we performed genome-wide association study (GWAS) analyses. Through collaboration with the Diabetes Nephropathy Collaborative Research Initiative, we assembled a large collection of type 1 diabetes cohorts with harmonized diabetic kidney disease phenotypes. We used a spectrum of ten diabetic kidney disease definitions based on albuminuria and renal function., Results: Our GWAS meta-analysis included association results for up to 19,406 individuals of European descent with type 1 diabetes. We identified 16 genome-wide significant risk loci. The variant with the strongest association (rs55703767) is a common missense mutation in the collagen type IV alpha 3 chain ( COL4A3) gene, which encodes a major structural component of the glomerular basement membrane (GBM). Mutations in COL4A3 are implicated in heritable nephropathies, including the progressive inherited nephropathy Alport syndrome. The rs55703767 minor allele (Asp326Tyr) is protective against several definitions of diabetic kidney disease, including albuminuria and ESKD, and demonstrated a significant association with GBM width; protective allele carriers had thinner GBM before any signs of kidney disease, and its effect was dependent on glycemia. Three other loci are in or near genes with known or suggestive involvement in this condition ( BMP7) or renal biology ( COLEC11 and DDR1 )., Conclusions: The 16 diabetic kidney disease-associated loci may provide novel insights into the pathogenesis of this condition and help identify potential biologic targets for prevention and treatment., (Copyright © 2019 by the American Society of Nephrology.)
- Published
- 2019
- Full Text
- View/download PDF
16. Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism.
- Author
-
Stechemesser L, Eder SK, Wagner A, Patsch W, Feldman A, Strasser M, Auer S, Niederseer D, Huber-Schönauer U, Paulweber B, Zandanell S, Ruhaltinger S, Weghuber D, Haschke-Becher E, Grabmer C, Rohde E, Datz C, Felder TK, and Aigner E
- Subjects
- Adult, Blood Glucose metabolism, Citrulline blood, Citrulline metabolism, Cross-Sectional Studies, Diabetes Mellitus, Type 2 metabolism, Female, Ferritins analysis, Ferritins blood, Ferritins metabolism, Glucose Tolerance Test, Homeostasis, Humans, Insulin Resistance physiology, Iron blood, Male, Metabolic Syndrome metabolism, Metabolomics methods, Middle Aged, Obesity blood, Sarcosine blood, Sarcosine metabolism, Glucose metabolism, Iron metabolism
- Abstract
Objective: Elevated serum ferritin has been linked to type 2 diabetes (T2D) and adverse health outcomes in subjects with the Metabolic Syndrome (MetS). As the mechanisms underlying the negative impact of excess iron have so far remained elusive, we aimed to identify potential links between iron homeostasis and metabolic pathways., Methods: In a cross-sectional study, data were obtained from 163 patients, allocated to one of three groups: (1) lean, healthy controls (n = 53), (2) MetS without hyperferritinemia (n = 54) and (3) MetS with hyperferritinemia (n = 56). An additional phlebotomy study included 29 patients with biopsy-proven iron overload before and after iron removal. A detailed clinical and biochemical characterization was obtained and metabolomic profiling was performed via a targeted metabolomics approach., Results: Subjects with MetS and elevated ferritin had higher fasting glucose (p < 0.001), HbA1c (p = 0.035) and 1 h glucose in oral glucose tolerance test (p = 0.002) compared to MetS subjects without iron overload, whereas other clinical and biochemical features of the MetS were not different. The metabolomic study revealed significant differences between MetS with high and low ferritin in the serum concentrations of sarcosine, citrulline and particularly long-chain phosphatidylcholines. Methionine, glutamate, and long-chain phosphatidylcholines were significantly different before and after phlebotomy (p < 0.05 for all metabolites)., Conclusions: Our data suggest that high serum ferritin concentrations are linked to impaired glucose homeostasis in subjects with the MetS. Iron excess is associated to distinct changes in the serum concentrations of phosphatidylcholine subsets. A pathway involving sarcosine and citrulline also may be involved in iron-induced impairment of glucose metabolism.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.